Abstract
In this paper, the estabished and possible roles of CCK1 and CCK2 receptors in gastrointestinal (GI) and metabolic diseases are reviewed and available results from human agonist/antagonist studies are discussed. While there is evidence for the involvement of CCK1R in numerous diseases including pancreatic disorders, motility disorders, tumor growth, regulation of satiety and a number of CCK-deficient states, the role of CCK1R in these conditions is not clearly defined. There are encouraging data from several clinical studies of CCK1R antagonists in some of these conditions, but their role as therapeutic agents remains unclear. The role of CCK2R in physiological (atrophic gastritis, pernicious anemia) and pathological (Zollinger-Ellison syndrome) hypergastrinemic states, its effects on the gastric mucosa (ECL cell hyperplasia, carcinoids, parietal cell mass) and its role in acid-peptic disorders are clearly defined. Furthermore, recent studies point to a possible role for CCK2R in a number of GI malignancies. Current data from human studies of CCK2R antagonists are presented and their potential role in the treatment of these conditions reviewed. Furthermore, the role of CCK2 receptors as targets for medical imaging is discussed.
Keywords: Pancreatic Disorders, gastric acid hypersecretion, Gallbladder Disease, Irritable Bowel Syndrome, Functional Dyspepsia, loxiglumide, CCK1R knockout mice
Current Topics in Medicinal Chemistry
Title: Role of CCK/Gastrin Receptors in Gastrointestinal/Metabolic Diseases and Results of Human Studies Using Gastrin/CCK Receptor Agonists/Antagonists in these Diseases
Volume: 7 Issue: 12
Author(s): Marc J. Berna and Robert T. Jensen
Affiliation:
Keywords: Pancreatic Disorders, gastric acid hypersecretion, Gallbladder Disease, Irritable Bowel Syndrome, Functional Dyspepsia, loxiglumide, CCK1R knockout mice
Abstract: In this paper, the estabished and possible roles of CCK1 and CCK2 receptors in gastrointestinal (GI) and metabolic diseases are reviewed and available results from human agonist/antagonist studies are discussed. While there is evidence for the involvement of CCK1R in numerous diseases including pancreatic disorders, motility disorders, tumor growth, regulation of satiety and a number of CCK-deficient states, the role of CCK1R in these conditions is not clearly defined. There are encouraging data from several clinical studies of CCK1R antagonists in some of these conditions, but their role as therapeutic agents remains unclear. The role of CCK2R in physiological (atrophic gastritis, pernicious anemia) and pathological (Zollinger-Ellison syndrome) hypergastrinemic states, its effects on the gastric mucosa (ECL cell hyperplasia, carcinoids, parietal cell mass) and its role in acid-peptic disorders are clearly defined. Furthermore, recent studies point to a possible role for CCK2R in a number of GI malignancies. Current data from human studies of CCK2R antagonists are presented and their potential role in the treatment of these conditions reviewed. Furthermore, the role of CCK2 receptors as targets for medical imaging is discussed.
Export Options
About this article
Cite this article as:
Marc J. Berna and Robert T. Jensen , Role of CCK/Gastrin Receptors in Gastrointestinal/Metabolic Diseases and Results of Human Studies Using Gastrin/CCK Receptor Agonists/Antagonists in these Diseases, Current Topics in Medicinal Chemistry 2007; 7 (12) . https://dx.doi.org/10.2174/156802607780960519
DOI https://dx.doi.org/10.2174/156802607780960519 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peptide-Receptor Ligands and Multivalent Approach
Anti-Cancer Agents in Medicinal Chemistry Nanoliposome is a Promising Carrier of Protein and Peptide Biomolecule for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Tumor-Targeting Peptides: Ligands for Molecular Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry Using β-Amino Acids and β-Peptide Templates to Create Bioactive Ligands and Biomaterials
Current Pharmaceutical Design Cellular Localisation of Chromogranins and Processed Products in the Diffuse Neuroendocrine System and Related Tumours
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Porphyrins as Radiosensitizing Agents for Solid Neoplasms
Current Pharmaceutical Design Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry Identifying Biomarkers of Lung Cancer in the Post-Genomic Era
Current Pharmacogenomics Rare Pulmonary Tumors and Carcinoma Mimickers; Experience from an Interventional Radiology Unit with Radiologic-pathologic Correlation- A Pictoral Essay
Current Medical Imaging Editorial [Hot Topic: Molecular Targeted Therapy of Gastrointestinal Cancer (Guest Editor: Marcus W. Wiedmann)]
Current Cancer Drug Targets Multifaceted Role of Neuropilins in Cancer
Current Medicinal Chemistry The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Current Molecular Medicine Adenocarcinoma of the Appendix in Elderly: Diagnostic Dilemma
New Emirates Medical Journal Toxicity and Tolerability of <sup>177</sup>Lu-DOTA-TATE PRRT with a Modified Administered Activity Protocol in NETs of Variable Origin – A Phase 2 Registry Study
Current Radiopharmaceuticals Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms
Endocrine, Metabolic & Immune Disorders - Drug Targets Differential Expressions of Matrix Metalloproteinases, A Disintegrin and Metalloproteinases, and a Disintegrin and Metalloproteinases with Thrombospondin Motifs and their Endogenous Inhibitors Among Histologic Subtypes of Lung Cancers
Anti-Cancer Agents in Medicinal Chemistry Role of Progastrins and Gastrins and Their Receptors in GI and Pancreatic Cancers: Targets for Treatment
Current Pharmaceutical Design Indirect Production of No Carrier Added (NCA) <sup>177</sup>Lu from Irradiation of Enriched <sup>176</sup>Yb: Options for Ytterbium/Lutetium Separation
Current Radiopharmaceuticals <sup>177</sup>Lu-Labeled Agents for Neuroendocrine Tumor Therapy and Bone Pain Palliation in Uruguay
Current Radiopharmaceuticals Peptide-based Radiopharmaceuticals for Targeted Tumor Therapy
Current Medicinal Chemistry